Nagler A, Or R, Nisman B, Kalickman I, Slavin S, Barak V
Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel.
Transplantation. 1995 Nov 15;60(9):943-8.
Graft rejection and graft failure represent major obstacles in allogeneic bone marrow transplantation (BMT). Cytokines possibly play a central role in the inflammatory and allospecific components of allograft rejection. Therefore, we evaluated inflammatory cytokine levels following BMT in 12 consecutive patients with graft rejection (GR). Seven of the patients underwent BMT from siblings (6 matched and 1 mismatched), 4 patients received bone marrow from other family members (3 mismatched and 1 matched), and 1 patient underwent HLA-matched unrelated BMT. Nine of 12 had a sex-mismatched BMT and 5/12 had an ABO-mismatched BMT. Nine of 12 underwent T cell-depleted (Campath anti-CDw52 moAb) BMT. Rejection was defined as marrow hypoplasia with a peripheral white blood cell count < 0.5 x 10(9)/L 21 days after BMT, in conjunction with the absence of donor cells by polymerase chain reaction analysis using a sex-mismatched probe and/or a tumor-specific probe (BCR/ABL). Twenty-five patients who underwent uneventful BMT with no GR served as controls. The levels of tumor necrosis factor (TNF), interleukin-6 (IL-6), and interleukin-1 (IL-1) were evaluated by a high sensitive RIA or an enzyme immunoassay. The levels of TNF and IL-6 were found to be higher in 10/12 and 7/7 evaluated GR patients, respectively, as compared with controls (P < 0.05). The level of IL-1 was high only in 2/12 patients. TNF elevation occurred in all patients immediately after GR. TNF and IL-6 levels were significantly higher for patients with early rejection (< 35 days after BMT) as compared with patients with late rejection (> 35 days after BMT) (P < 0.049 and P < 0.006, respectively). Eight patients engrafted after the second transplant (2 only transient). All 6 patients with stable engraftment are alive (4 with basic disease), while the 4 patients who did not engraft and the 2 patients with only transient engraftment died. In the 6 patients with no engraftment or only transient engraftment, the elevated TNF levels remained high; in the 6 patients who had stable engraftment after retransplant, TNF levels, but not IL-6 levels, decreased. In conclusion, a majority of the patients with GR displayed high levels of inflammatory cytokines (TNF and IL-6). Dysregulation of inflammatory cytokines may be involved in the pathogenesis of GR.
移植物排斥和移植物衰竭是同种异体骨髓移植(BMT)中的主要障碍。细胞因子可能在同种异体移植物排斥的炎症和同种特异性成分中起核心作用。因此,我们评估了12例连续发生移植物排斥(GR)的患者在BMT后的炎症细胞因子水平。其中7例患者接受了同胞的BMT(6例匹配,1例不匹配),4例患者接受了其他家庭成员的骨髓(3例不匹配,1例匹配),1例患者接受了HLA匹配的无关供体BMT。12例患者中有9例进行了性别不匹配的BMT,5/12进行了ABO血型不匹配的BMT。12例患者中有9例接受了去除T细胞(Campath抗CDw52单克隆抗体)的BMT。排斥反应的定义为BMT后21天骨髓发育不全,外周血白细胞计数<0.5×10⁹/L,同时使用性别不匹配探针和/或肿瘤特异性探针(BCR/ABL)通过聚合酶链反应分析未检测到供体细胞。25例接受BMT且无GR的患者作为对照。通过高灵敏度放射免疫分析或酶免疫测定评估肿瘤坏死因子(TNF)、白细胞介素-6(IL-6)和白细胞介素-1(IL-1)的水平。与对照组相比,分别在10/12和7/7例评估的GR患者中发现TNF和IL-6水平升高(P<0.05)。IL-1水平仅在2/12例患者中升高。GR后所有患者立即出现TNF升高。与晚期排斥患者(BMT后>35天)相比,早期排斥患者(BMT后<35天)的TNF和IL-6水平显著更高(分别为P<0.049和P<0.006)。8例患者在第二次移植后植入(2例仅为短暂植入)。所有6例植入稳定的患者均存活(4例患有基础疾病),而4例未植入和2例仅短暂植入的患者死亡。在6例未植入或仅短暂植入的患者中,升高的TNF水平仍然很高;在6例再次移植后植入稳定的患者中,TNF水平下降,但IL-6水平未下降。总之,大多数GR患者表现出高水平的炎症细胞因子(TNF和IL-6)。炎症细胞因子失调可能参与了GR的发病机制。